Close this search box.

Over 1,000 notified body applications per month. Will your device be among them?

Do the math: Regulation 2023/607 The MDR was created under the assumption that manufacturers would be able to switch from the AIMDD and MDD to the MDR during their normal certification cycle. However, it took years before the first notified body was designated and the designation process is still ongoing, supporting structures, like EUDAMED, expert … Read more

Regulation (EU) 2023/607 MDR transitional arrangements for Class III and Class IIb, implantable devices

This section is about: Regulation (EU) 2023/607 Regulation (EU) 2023/607 on MDR transitional arrangements allows for manufacturers of devices that were certified under the ‘old’ Directives to remain certified as such for some years to come, while they wait until they become certified under the MDR. In general, this will require the manufacturer to prepare … Read more

MDR Amendment Regulation (EU) 2023/607

how this may (not) work for you Elevator pitch The new amendment to the MDR is nicknamed the ‘MDR Extension Regulation’. This has some truth in it, but it does not cover the whole story. It may also create incorrect expectations with stakeholders. So here is the one-sentence elevator pitch I would recommend preparing, in … Read more

Feasibility check for the applicability of MDR Article 97

Expiring certificate At this moment AIMDD or MDD certificates may expire before a new MDR certificate is issued. In that case, a manufacturer may lose access to the EU market. MDCG 2022-18 provides guidance about how the Competent Authorities will handle the specific situation when a non-conformity is created by the expiration of a certificate … Read more

Quick due diligence checklist non-integral DDC

Pharmaceutical companies that want to place a non-integral drug-device combination on the EU market need to work together with a medical device manufacturer. The device must be CE-certified for the right intended purpose before the market authorization application can be filed. Therefore, it is important for the drug company to keep sufficient control over the … Read more

Case: Missed mixed status devices in a system

Incorporated IVD A multi-component device is intended to be used surgically invasive, where a specific intervention can be performed via a minimally invasive technique. During this operation, a sample can be taken and stored in a container for transfer to the lab. Sampling is optional, it is not the main objective of this intervention. When … Read more

Article 54/59 derogation – yes, it can be done, but I rather suggest you should try not having to depend on it…

Article 59 MDR/Article 54 IVDR Article 59 (1) says: ‘By way of derogation from Article 52 of this Regulation (…), any competent authority may authorise, on a duly justified request, the placing on the market or putting into service within the territory of the Member State concerned, of a specific device for which the applicable … Read more

Check your consistency, your notified body will do that for sure

Helping your notified body working efficiently We all know that notified bodies are in short supply and they should work as efficient as possible. There is something we can all do to help: prepare documentation well. It sounds obvious, but I still have to explain to companies that notified body reviewers want to see clear, … Read more